Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Telix Pharmaceuticals Limited

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Illuccix® Approved in the United Kingdom
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Completes Acquisition of RLS (USA) Inc.
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Illuccix® Receives European Approval
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix ADSs Commence Trading on Nasdaq
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX CAH
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Reorganisation to Deliver on Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.